| Literature DB >> 30612738 |
Ron D Jachimowicz1, Filippo Beleggia2, Jörg Isensee3, Bhagya Bhavana Velpula4, Jonas Goergens5, Matias A Bustos6, Markus A Doll7, Anjana Shenoy8, Cintia Checa-Rodriguez9, Janica Lea Wiederstein10, Keren Baranes-Bachar4, Christoph Bartenhagen11, Falk Hertwig12, Nizan Teper4, Tomohiko Nishi6, Anna Schmitt5, Felix Distelmaier13, Hermann-Josef Lüdecke14, Beate Albrecht15, Marcus Krüger16, Björn Schumacher7, Tamar Geiger8, Dave S B Hoon6, Pablo Huertas9, Matthias Fischer11, Tim Hucho3, Martin Peifer17, Yael Ziv18, H Christian Reinhardt19, Dagmar Wieczorek20, Yosef Shiloh21.
Abstract
Genomic instability can be a hallmark of both human genetic disease and cancer. We identify a deleterious UBQLN4 mutation in families with an autosomal recessive syndrome reminiscent of genome instability disorders. UBQLN4 deficiency leads to increased sensitivity to genotoxic stress and delayed DNA double-strand break (DSB) repair. The proteasomal shuttle factor UBQLN4 is phosphorylated by ATM and interacts with ubiquitylated MRE11 to mediate early steps of homologous recombination-mediated DSB repair (HRR). Loss of UBQLN4 leads to chromatin retention of MRE11, promoting non-physiological HRR activity in vitro and in vivo. Conversely, UBQLN4 overexpression represses HRR and favors non-homologous end joining. Moreover, we find UBQLN4 overexpressed in aggressive tumors. In line with an HRR defect in these tumors, UBQLN4 overexpression is associated with PARP1 inhibitor sensitivity. UBQLN4 therefore curtails HRR activity through removal of MRE11 from damaged chromatin and thus offers a therapeutic window for PARP1 inhibitor treatment in UBQLN4-overexpressing tumors.Entities:
Keywords: DNA damage; DNA double-strand break repair; UBQLN4 deficiency syndrome; cancer; genome instability syndrome; homologous recombination; non-homologous end joining; proteasomal degradation; targeted cancer therapy; ubiquitin
Mesh:
Substances:
Year: 2019 PMID: 30612738 DOI: 10.1016/j.cell.2018.11.024
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582